Quarterly ResultApr 9, 2026, 04:07 PM
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, Up 4.1% Year-Over-Year
AI Summary
Sunshine Biopharma Inc. announced its financial results for the fiscal year ended December 31, 2025, reporting total revenue of $36.3 million. This represents a 4.1% increase compared to the prior year, indicating continued top-line growth for the pharmaceutical company. The company focuses on developing life-saving medicines across oncology, antivirals, and other key therapeutic areas, and this revenue growth suggests progress in its commercialization or development efforts.
Key Highlights
- Reported fiscal year 2025 revenue of $36.3 million.
- Achieved a 4.1% increase in revenue over the prior year.
- Sunshine Biopharma operates as a pharmaceutical company developing medicines in oncology, antivirals, and other key therapeutic areas.